Γενόσημα: ρυθμιστικό πλαίσιο και αντιλήψεις στην Ελλάδα
Generics: regulatory framework and perceptions in Greece
View/
Keywords
Γενόσημα ; Φαρμακευτική δαπάνη ; Κίνητρα ; ΑντιλήψειςAbstract
Generic pharmaceutical products have been proposed as a solution to curb the increasing pharmaceutical costs in the EU countries and in Greece as well, in the frame of saving health care costs.
For Greece, the increase of generics’ use medicines has also been an objective in the Fiscal Adjustment Program.
However, after 11 years of measures and discussions, the rate of use of generic medicines in Greece is far from that of the European Union and, as far as the OECD countries are concerned, Greece ranks fourth from the end, i.e., the percentage of generic medicines in the volume of medicines received by insured persons is 24%.
Concerning the question why generics have low penetration in Greece, answers have been given focusing on the lack of incentives on the part of health care professionals/prescribers, reluctance due to low price and high taxation (mandatory discounts and rebates) on the part of pharmaceutical companies.
In this thesis, we will analyze the regulatory framework with regard to the approval, pricing and reimbursement of generic medicines, health care and drug expenditure, in Greece.
Finally, the responses obtained from a questionnaire addressed to Greek physicians and pharmacists, their perceptions and opinions on generic drugs and whether and to what extent they have changed in recent years will be analyzed.
Postgraduate Studies Programme
Οικονομικά και Διοίκηση της ΥγείαςDepartment
Σχολή Οικονομικών, Επιχειρηματικών και Διεθνών Σπουδών. Τμήμα Οικονομικής ΕπιστήμηςNumber of pages
104Language
GreekCollections
Except where otherwise noted, this item's license is described as
Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ελλάδα
Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ελλάδα